Jolanta Kupryjanczyk

List of Publications by Citations

19 papers	1,612 citations	15 h-index	22 g-index
22 ext. papers	1,924 ext. citations	11.1 avg, IF	2.66 L-index

#	Paper	IF	Citations
19	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. *Nature Genetics*, **2013**, 45, 371-84, 384e1-2	36.3	422
18	GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. *Nature Genetics*, **2013**, 45, 362-70, 370e1-2	36.3	267
17	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. *Nature Genetics*, **2017**, 49, 680-691	36.3	190
16	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. *Nature Genetics*, **2015**, 47, 164-71	36.3	177
15	Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. *Nature Communications*, **2013**, 4, 1628	17.4	124
14	Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types. *Cancer Discovery*, **2016**, 6, 1052-67	24.4	104
13	A novel germline PALB2 deletion in Polish breast and ovarian cancer patients. *BMC Medical Genetics* , **2010**, 11, 20	2.1	86
12	Gene expression analysis in ovarian cancer - faults and hints from DNA microarray study. *Frontiers in Oncology*, **2014**, 4, 6	5.3	55
11	The putative oncogene, CRNDE, is a negative prognostic factor in ovarian cancer patients. *Oncotarget*, **2015**, 6, 43897-910	3.3	46
10	Unsupervised analysis reveals two molecular subgroups of serous ovarian cancer with distinct gene expression profiles and survival. *Journal of Cancer Research and Clinical Oncology*, **2016**, 142, 1239-52	4.9	20
9	High frequency of allelic loss at the BRCA1 locus in ovarian cancers: clinicopathologic and molecular associations. *Cancer Genetics*, **2012**, 205, 94-100	2.3	18
8	TP53, BCL-2 and BAX analysis in 199 ovarian cancer patients treated with taxane-platinum regimens. *Gynecologic Oncology*, **2009**, 112, 179-84	4.9	18
7	TP53 status and taxane-platinum versus platinum-based therapy in ovarian cancer patients: a non-randomized retrospective study. *BMC Cancer*, **2008**, 8, 27	4.8	18
6	Fibronectin and Periostin as Prognostic Markers in Ovarian Cancer. *Cells*, **2020**, 9,	7.9	17
5	Nuclear survivin expression is a positive prognostic factor in taxane-platinum-treated ovarian cancer patients. *Journal of Ovarian Research*, **2011**, 4, 20	5.5	17
4	Clinical importance of FANCD2, BRIP1, BRCA1, BRCA2 and FANCF expression in ovarian carcinomas. *Cancer Biology and Therapy*, **2019**, 20, 843-854	4.6	9
3	Prognosis of patients with BRCA1-associated ovarian carcinomas depends on TP53 accumulation status in tumor cells. *Gynecologic Oncology*, **2017**, 144, 369-376	4.9	7

2	Cross-Cancer Genome-Wide Association Study of Endometrial Cancer and Epithelial Ovarian Cancer Identifies Genetic Risk Regions Associated with Risk of Both Cancers. *Cancer Epidemiology Biomarkers and Prevention*, **2021**, 30, 217-228	4	7
1	Menopausal hormone therapy prior to the diagnosis of ovarian cancer is associated with improved survival. *Gynecologic Oncology*, **2020**, 158, 702-709	4.9	5